3274 related articles for article (PubMed ID: 7600560)
21. Effects of a combination of cyclophosphamide and human recombinant interleukin 2 on pulmonary metastasis after the surgical removal of a 3-methylcholanthrene-induced primary tumor in autochthonous mice.
Hosokawa M; Yabiku T; Ikeda J; Sawamura Y; Okada F; Komatsumoto M; Tanabe T; Kobayashi H
Jpn J Cancer Res; 1988 Oct; 79(10):1147-54. PubMed ID: 3143703
[TBL] [Abstract][Full Text] [Related]
22. Modulation of hematologic and immunologic effects of high dose chemotherapy by interleukin-2 in a murine tumor model.
Rinehart JJ; Triozzi PL; Lee MH; Aldrich W; Young D
Mol Biother; 1992 Jun; 4(2):77-82. PubMed ID: 1515098
[TBL] [Abstract][Full Text] [Related]
23. Effect of cyclophosphamide and levan treatment on bone marrow and peripheral blood cells in B16-F10 melanoma-bearing mice.
Leibovici J; Siegal A; Kopel S; Davidai G; Yavetz H
Int J Immunopharmacol; 1989; 11(2):133-47. PubMed ID: 2703278
[TBL] [Abstract][Full Text] [Related]
24. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice.
Johnson EE; Buhtoiarov IN; Baldeshwiler MJ; Felder MA; Van Rooijen N; Sondel PM; Rakhmilevich AL
J Immunother; 2011 Jan; 34(1):76-84. PubMed ID: 21150715
[TBL] [Abstract][Full Text] [Related]
25. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases.
Vidal-Vanaclocha F; Amézaga C; Asumendi A; Kaplanski G; Dinarello CA
Cancer Res; 1994 May; 54(10):2667-72. PubMed ID: 8168095
[TBL] [Abstract][Full Text] [Related]
27. In situ detection of immunocompetent cells in murine B16 melanoma locally treated with interleukin-2 or microwaval hyperthermia.
Nakayama J; Urabe A; Terao H; Taniguchi S; Hori Y
Pigment Cell Res; 1993 Mar; 6(2):111-6. PubMed ID: 8100634
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
29. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
30. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
31. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2.
Safwat A; Aggerholm N; Roitt I; Overgaard J; Hokland M
Eur J Cancer; 2004 Jun; 40(9):1412-7. PubMed ID: 15177501
[TBL] [Abstract][Full Text] [Related]
32. Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Lee CH; Kakinuma T; Wang J; Zhang H; Palmer DC; Restifo NP; Hwang ST
Mol Cancer Ther; 2006 Oct; 5(10):2592-9. PubMed ID: 17041104
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo comparison between the effects of treatment with adenosine triphosphate and treatment with buthionine sulfoximine on chemosensitization and tumour growth of B16 melanoma.
Palomares T; Bilbao P; del Olmo M; Castro B; Calle Y; Alonso-Varona A
Melanoma Res; 1999 Jun; 9(3):233-42. PubMed ID: 10465578
[TBL] [Abstract][Full Text] [Related]
34. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
35. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
Lala PK; Parhar RS
Cancer Res; 1988 Mar; 48(5):1072-9. PubMed ID: 3124954
[TBL] [Abstract][Full Text] [Related]
36. Combined effect of interleukin 2 and cyclophosphamide in therapy of mice with transitional cell carcinoma.
Ikemoto S; Kamizuru M; Wada S; Hayahara N; Nishio S; Kishimoto T; Maekawa M
Urology; 1992 Dec; 40(6):574-8. PubMed ID: 1466115
[TBL] [Abstract][Full Text] [Related]
37. Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy.
Katz A; Shulman LM; Porgador A; Revel M; Feldman M; Eisenbach L
J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):98-109. PubMed ID: 8318501
[TBL] [Abstract][Full Text] [Related]
38. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.
Goldfarb RH; Kitson RP; Brunson KW; Yoshino K; Hirota N; Kirii Y; Kotera Y; Inoue Y; Ohashi M
Anticancer Res; 1999; 19(3A):1663-7. PubMed ID: 10470098
[TBL] [Abstract][Full Text] [Related]
39. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
40. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
